WEST PHARMACEUTICAL SERVICES (WST) Fundamental Analysis & Valuation
NYSE:WST • US9553061055
Current stock price
302.21 USD
-3.95 (-1.29%)
Last:
This WST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. WST Profitability Analysis
1.1 Basic Checks
- WST had positive earnings in the past year.
- WST had a positive operating cash flow in the past year.
- In the past 5 years WST has always been profitable.
- In the past 5 years WST always reported a positive cash flow from operatings.
1.2 Ratios
- WST has a Return On Assets of 13.21%. This is amongst the best in the industry. WST outperforms 96.49% of its industry peers.
- WST has a better Return On Equity (18.15%) than 91.23% of its industry peers.
- With an excellent Return On Invested Capital value of 16.07%, WST belongs to the best of the industry, outperforming 94.74% of the companies in the same industry.
- WST had an Average Return On Invested Capital over the past 3 years of 15.83%. This is above the industry average of 11.41%.
- The 3 year average ROIC (15.83%) for WST is below the current ROIC(16.07%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.21% | ||
| ROE | 18.15% | ||
| ROIC | 16.07% |
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
1.3 Margins
- The Profit Margin of WST (16.85%) is better than 84.21% of its industry peers.
- WST's Profit Margin has been stable in the last couple of years.
- WST's Operating Margin of 21.24% is amongst the best of the industry. WST outperforms 87.72% of its industry peers.
- WST's Operating Margin has been stable in the last couple of years.
- WST has a worse Gross Margin (36.28%) than 61.40% of its industry peers.
- WST's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.24% | ||
| PM (TTM) | 16.85% | ||
| GM | 36.28% |
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
2. WST Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so WST is still creating some value.
- Compared to 1 year ago, WST has less shares outstanding
- WST has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, WST has an improved debt to assets ratio.
2.2 Solvency
- WST has an Altman-Z score of 15.02. This indicates that WST is financially healthy and has little risk of bankruptcy at the moment.
- WST's Altman-Z score of 15.02 is amongst the best of the industry. WST outperforms 98.25% of its industry peers.
- WST has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
- The Debt to FCF ratio of WST (0.45) is better than 92.98% of its industry peers.
- WST has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
- WST's Debt to Equity ratio of 0.07 is fine compared to the rest of the industry. WST outperforms 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 15.02 |
ROIC/WACC1.48
WACC10.86%
2.3 Liquidity
- A Current Ratio of 2.71 indicates that WST has no problem at all paying its short term obligations.
- WST's Current ratio of 2.71 is in line compared to the rest of the industry. WST outperforms 50.88% of its industry peers.
- WST has a Quick Ratio of 2.04. This indicates that WST is financially healthy and has no problem in meeting its short term obligations.
- WST has a Quick ratio (2.04) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.04 |
3. WST Growth Analysis
3.1 Past
- WST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.03%, which is quite impressive.
- WST shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.94% yearly.
- Looking at the last year, WST shows a quite strong growth in Revenue. The Revenue has grown by 11.23% in the last year.
- The Revenue has been growing slightly by 7.44% on average over the past years.
EPS 1Y (TTM)20.03%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%46.9%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%21.05%
3.2 Future
- Based on estimates for the next years, WST will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.01% on average per year.
- The Revenue is expected to grow by 7.95% on average over the next years.
EPS Next Y11.24%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
EPS Next 5Y9.01%
Revenue Next Year6.04%
Revenue Next 2Y6.13%
Revenue Next 3Y6.47%
Revenue Next 5Y7.95%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. WST Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 37.92, the valuation of WST can be described as expensive.
- Based on the Price/Earnings ratio, WST is valued a bit cheaper than 63.16% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.42, WST is valued a bit more expensive.
- Based on the Price/Forward Earnings ratio of 33.62, the valuation of WST can be described as expensive.
- Based on the Price/Forward Earnings ratio, WST is valued a bit cheaper than 63.16% of the companies in the same industry.
- WST is valuated expensively when we compare the Price/Forward Earnings ratio to 22.29, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.92 | ||
| Fwd PE | 33.62 |
4.2 Price Multiples
- WST's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. WST is cheaper than 61.40% of the companies in the same industry.
- The rest of the industry has a similar Price/Free Cash Flow ratio as WST.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.56 | ||
| EV/EBITDA | 25.27 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- WST has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.37
PEG (5Y)4.24
EPS Next 2Y11.04%
EPS Next 3Y11.52%
5. WST Dividend Analysis
5.1 Amount
- WST has a yearly dividend return of 0.33%, which is pretty low.
- WST's Dividend Yield is rather good when compared to the industry average which is at 0.11. WST pays more dividend than 84.21% of the companies in the same industry.
- With a Dividend Yield of 0.33, WST pays less dividend than the S&P500 average, which is at 1.81.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
5.2 History
- The dividend of WST has a limited annual growth rate of 5.48%.
- WST has paid a dividend for at least 10 years, which is a reliable track record.
- WST has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)5.48%
Div Incr Years33
Div Non Decr Years34
5.3 Sustainability
- 11.39% of the earnings are spent on dividend by WST. This is a low number and sustainable payout ratio.
- The dividend of WST is growing, but earnings are growing more, so the dividend growth is sustainable.
DP11.39%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
WST Fundamentals: All Metrics, Ratios and Statistics
NYSE:WST (4/27/2026, 11:49:08 AM)
302.21
-3.95 (-1.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-23 2026-04-23/bmo
Earnings (Next)07-22 2026-07-22/bmo
Inst Owners97.62%
Inst Owner Change-0.55%
Ins Owners0.29%
Ins Owner Change0.38%
Market Cap21.78B
Revenue(TTM)3.22B
Net Income(TTM)542.70M
Analysts80.87
Price Target328.99 (8.86%)
Short Float %4.08%
Short Ratio3.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP11.39%
Div Incr Years33
Div Non Decr Years34
Ex-Date04-29 2026-04-29 (0.22)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18%
Min EPS beat(2)10.24%
Max EPS beat(2)25.77%
EPS beat(4)4
Avg EPS beat(4)18.02%
Min EPS beat(4)10.24%
Max EPS beat(4)25.77%
EPS beat(8)7
Avg EPS beat(8)12.73%
EPS beat(12)11
Avg EPS beat(12)12.39%
EPS beat(16)14
Avg EPS beat(16)12.42%
Revenue beat(2)2
Avg Revenue beat(2)3.79%
Min Revenue beat(2)0.33%
Max Revenue beat(2)7.25%
Revenue beat(4)4
Avg Revenue beat(4)3.25%
Min Revenue beat(4)0.33%
Max Revenue beat(4)7.25%
Revenue beat(8)7
Avg Revenue beat(8)1.68%
Revenue beat(12)8
Avg Revenue beat(12)0.96%
Revenue beat(16)11
Avg Revenue beat(16)0.86%
PT rev (1m)0%
PT rev (3m)-7.08%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)1.61%
EPS NY rev (1m)0.09%
EPS NY rev (3m)3.32%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)2.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.92 | ||
| Fwd PE | 33.62 | ||
| P/S | 6.76 | ||
| P/FCF | 47.56 | ||
| P/OCF | 30.45 | ||
| P/B | 7.28 | ||
| P/tB | 7.58 | ||
| EV/EBITDA | 25.27 |
EPS(TTM)7.97
EY2.64%
EPS(NY)8.99
Fwd EY2.97%
FCF(TTM)6.35
FCFY2.1%
OCF(TTM)9.92
OCFY3.28%
SpS44.69
BVpS41.49
TBVpS39.88
PEG (NY)3.37
PEG (5Y)4.24
Graham Number86.2537 (-71.46%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.21% | ||
| ROE | 18.15% | ||
| ROCE | 19.91% | ||
| ROIC | 16.07% | ||
| ROICexc | 18.95% | ||
| ROICexgc | 19.73% | ||
| OM | 21.24% | ||
| PM (TTM) | 16.85% | ||
| GM | 36.28% | ||
| FCFM | 14.22% |
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
ROICexc(3y)20.32%
ROICexc(5y)23.97%
ROICexgc(3y)21.34%
ROICexgc(5y)25.37%
ROCE(3y)19.61%
ROCE(5y)22.21%
ROICexgc growth 3Y-13.74%
ROICexgc growth 5Y-3.06%
ROICexc growth 3Y-13.28%
ROICexc growth 5Y-2.17%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.24 | ||
| Cap/Depr | 145.7% | ||
| Cap/Sales | 7.99% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 83.1% | ||
| Profit Quality | 84.39% | ||
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 15.02 |
F-Score7
WACC10.86%
ROIC/WACC1.48
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)20.03%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%46.9%
EPS Next Y11.24%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
EPS Next 5Y9.01%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%21.05%
Revenue Next Year6.04%
Revenue Next 2Y6.13%
Revenue Next 3Y6.47%
Revenue Next 5Y7.95%
EBIT growth 1Y16.64%
EBIT growth 3Y-5.8%
EBIT growth 5Y8.6%
EBIT Next Year43.62%
EBIT Next 3Y20.28%
EBIT Next 5Y16.28%
FCF growth 1Y18.62%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y-5.46%
OCF growth 3Y1.4%
OCF growth 5Y9.82%
WEST PHARMACEUTICAL SERVICES / WST Fundamental Analysis FAQ
What is the fundamental rating for WST stock?
ChartMill assigns a fundamental rating of 7 / 10 to WST.
What is the valuation status for WST stock?
ChartMill assigns a valuation rating of 3 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Overvalued.
How profitable is WEST PHARMACEUTICAL SERVICES (WST) stock?
WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 8 / 10.
What is the financial health of WEST PHARMACEUTICAL SERVICES (WST) stock?
The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.
What is the expected EPS growth for WEST PHARMACEUTICAL SERVICES (WST) stock?
The Earnings per Share (EPS) of WEST PHARMACEUTICAL SERVICES (WST) is expected to grow by 11.24% in the next year.